Supriya Lifescience Limited has informed the Exchange about Investor Presentation
Date: January 24, 2025
To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543434 Scrip Symbol: SUPRIYA
Bandra Kurla Complex
Dear Sir/Madam,
Subject: Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation.
You are requested to kindly take the same on record.
Thanking you,
For Supriya Lifescience Limited
Shweta Singh Company Secretary & Compliance Officer Membership No.: A44973
Corporate office
: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX Tel: +91 22 40332727 / 66942507
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com
GOVT. RECOGNISED EXPORT HOUSE
SUPRIYA LIFESCIENCE LTD.
Investor Presentation | Q3 & 9M FY25
Safe Harbour
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information
purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any
contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information
about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express
or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not
be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly
excluded
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-
looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are
difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the
performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion,
technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other
risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The
Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included
in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
Q3 FY25 Earnings Presentation
2
Q3 & 9M FY25 Highlights
Q3 FY25 Highlights
y l r e t r a u Q
e c n a m r o f r e P l a n o i g e R
Revenue
EBITDA
PBT
PAT
(in INR Mn)
Rs. 1856.5 Mn
Rs. 659.5 Mn
Rs. 625.8 Mn
Rs. 467.8 Mn
33% YoY
59% YoY
56% YoY
57% YoY
Business Mix Revenue Contribution – By Region
42%
32% 31%
42%
38% 40%
19% 21%
8%
5% 5% 3%
4% 6% 5%
Asia
Europe
LAC
North America
Others
Q3 FY24 Q2 FY25 Q3 FY25
4
Q3 FY25 Earnings Presentation
9M FY25 Highlights
Revenue
EBITDA
PBT
PAT
(in INR Mn)
Rs. 5,123.8 Mn
Rs. 1,932.1 Mn
Rs. 1,844.2 Mn
Rs. 1,375.8 Mn
24% YoY
64% YoY
64% YoY
67% YoY
Business Mix Revenue Contribution – By Region
40%
32%
41% 43%
17%
9%
6% 4%
Asia
Europe
LAC
North America
9M FY24 9M FY25
5
4%
4%
Others
y l r e t r a u Q
e c n a m r o f r e P l a n o i g e R
Q3 FY25 Earnings Presentation
Q3 & 9M FY25 - Y-o-Y Highlights
Revenue
EBITDA
PBT
PAT
(in INR Mn)
+24%
5,123.8
4,121.9
+33%
1,400.7
1,856.5
+64%
1,932.1
+64%
1,844.2
+67%
1,375.8
1,174.7
+59%
1,125.2
+56%
821.8
659.5
414.9
625.8
401.0
+57%
467.8
297.8
9MFY24 9MFY25 Q3FY24 Q3FY25
9MFY24 9MFY25 Q3FY24 Q3FY25
9MFY24 9MFY25 Q3FY24 Q3FY25
9MFY24 9MFY25 Q3FY24 Q3FY25
EBITDA Margins
PAT Margins
+921 bps
+591 bps
38%
36%
30%
28%
+691 bps
+394 bps
27%
25%
21%
20%
Q3 FY25 Earnings Presentation
6
9MFY24 9MFY25 Q3FY24 Q3FY25
9MFY24 9MFY25 Q3FY24 Q3FY25
Business Mix Revenue Contribution – By Therapy
Performance of the Therapeutic Areas
Y-o-Y
60%
49%
15%
12%
14%
10%
7%
4%
5%
4%
2%
1%
Analgesic/Anesthetic
Anti-histamine
Vitamins
Anti-Asthmatic
Anti-allergic
Anti-hypertensive
Q3 FY25 Earnings Presentation
7
Q3FY24
Q3FY25
Q3 & 9M FY25 Profit & Loss Statement
Particulars (in INR Mn)
Revenue from Operations
Cost of Materials Consumed
Changes in Inventories of Finished Goods and Work in Progress
Gross Profit
GP %
Employee Benefits Expense
Other Expenses
EBITDA
EBITDA %
Other Income
Depreciation and Amortisation Expense
EBIT
Finance Costs
PBT
Total Tax Expense
Profit for the year
PAT %
EPS
Q3 FY25 Earnings Presentation
Q3 FY25
Q3 FY24
1,856.5
626.8
-9.0
1,238.7
66.7%
197.7
381.4
659.5
35.5%
21.0
49.6
630.9
5.1
625.8
158.0
467.8
25.2%
5.82
1,400.7
448.4
97.8
854.5
61.0%
175.6
264.0
414.9
29.6%
30.7
39.6
405.9
4.9
401.0
103.1
297.8
21.3%
3.70
Y-o-Y
33%
45%
+572 Bps
59%
Q2 FY25
1661.0
615.8
-156.1
1,201.3
72.3%
196.9
357.3
647.2
+591 Bps
39.0%
55%
56%
57%
+394 Bps
25.2
47.4
624.9
4.3
620.6
159.2
461.5
27.8%
5.71
Q-o-Q
12%
9M FY25
9M FY24
5,123.8
1,799.9
4,121.9
1,430.7
-236.4
204.1
Y-o-Y
24%
3%
3,560.3
2,487.1
43%
2%
1%
1%
1%
69.5%
595.4
1032.7
1,932.1
37.7%
68.4
143.6
+915 Bps
60.3%
504.9
807.4
1,174.7
64%
+921 Bps
28.5%
84.5
119.0
1,856.9
1,140.2
63%
12.7
1,844.2
468.4
1,375.8
26.9%
17.07
15.1
1,125.2
303.3
821.8
19.9%
10.21
64%
67%
+691 Bps
8
Company Overview
Business Overview
Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics
40+ APIs
120+ Countries
33,000 Sq.mts
932 KLPD
Niche product basket
Diversified operations with presence
Manufacturing facility spread across
Reactor capacity
WHO-GMP, Written Confirmation, ISO, Halal, Indonesian Halal. Fami QS
15
DMFs with USFDA
9 CEP granted 4 CEP applied
1,500+
customers
3 Times USFDA approved
2 times EUGMP/EDQM approved
HEALTH CANADA
COFEPRIS
ANVISA
KFDA
NMPA
TGA
AIFA
Q3 FY25 Earnings Presentation
10
Journey So Far
2020
2021
2022
2023
2024
Third time USFDA approval
CEP granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate; NMPA approval granted; Health Canada approval
Listed on Stock Exchange BSE & NSE
CEP (Certificate of suitability ) renewed for Pheniramine Maleate, Chlorpheniramine Maleate and Ketamine Hydrochloride
The Company commenced operations at its new R&D lab in Lote Parshuram
ANVISA Approval Granted
2018
2017
2015
2014
2013
CEP granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride
CEP granted for Pheniramine Maleate; Second time USFDA approval granted
EUGMP and EDQM approval granted
USFDA approval granted; IDL granted for Brompheniramine Maleate
COFEPRIS and KFDA approval granted
2008
2009
2010
2011
Incorporation & conversion from a partnership firm to a public limited company
Started production of Ketamine hydrochloride
CEP granted for Chlorphenamine Maleate
IDL granted for Chlorphenamine Maleate
11
Q3 FY25 Earnings Presentation
Backward Integrated Business Model
Supply Security
Low Price Risk
In-House Processes
Steady supply of essential raw materials
Protection against market fluctuations
Less Dependence On External Parties
Cost-competitive Structure
Increasing margins
15 products are backward integrated* in following therapies
Anesthetics
Anti-Asthmatic
Anti-Histamine
Decongestant
Anti-Gout
77%
of Q3 FY25 revenue
Integrated business model helped us grow revenue and sustain margins in the last year. Large part of growth and sustainability was driven by these backward integrated products
Note: In the process of further backward integrating 3 more products
Q3 FY25 Earnings Presentation
* As on 31st December 2023
12
Diversified Geographic Presence
For key products we are seeing good traction in untapped regulated markets of North America
For Anaesthetic therapy 3 ANDA projects have been initiated and we are also working on ANDA projects for Anti Hypertensive and Vitamins
Presence in 86+ Countries Across Globe
Q3 FY25 Earnings Presentation
13
Diversified Revenues with Extensive Global Presence
Significant export presence, with low dependence on a specific geography
… with customer concentration
Export sales, as a % of revenue from operations
Share of top 10 customers, as a % of revenue from operations
77%
76%
80%
79%
40%
47%
45%
49%
FY21
FY22
FY23
FY24
FY21
FY22
FY23
FY24
Long standing relationship with global pharma companies …
… We plan to reduce customer concentration
Penetration of existing products to newer geographies by registering these products
Adding new niche products with high volume potential for which we are building 2 new R&D centers
CMO/CDMO opportunities
Q3 FY25 Earnings Presentation
14
Advanced Manufacturing and R&D Capabilities
o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, for engineering maintenance, dedicated areas warehouse, raw materials, packaging materials and finished goods stores
o Newly commissioned Effluent treatment plant for future volume growth and express feeder from the sub-station to ensure reliable power supply
o Recently commissioned new warehouses and administration block, with new Quality Control Labs, Quality Assurance and R&D Labs (IGBC Gold Certified)
o Strategic Land Acquisitions:
5 Manufacturing Blocks
9 Clean Rooms
932 KLPD Reactor Capacity
33,000sq.mt. Land Area
Scaled up Manufacturing Facilities over the years
Steady improvement in capacity utilization
➢ 12,551 sq.mt.: Adjacent to the existing facility to enable seamless future growth and expansion
Block A
Block B
Block C
Block D
Block E
➢ 24,646 sq.mt.: Located 20 km from the current for backward
facility, strategically acquired integration to enhance operational efficiency
➢ 80,000 sq.mt.: Situated at Isambe, Patalganga, near the upcoming Navi Mumbai International Airport.
Q3 FY25 Earnings Presentation
Year of Establishment
1993
1994
2014
2021
2024
Capacities
157 KLPD 195 KLPD 30 KLPD 215 KLPD 335 KLPD
Regulatory Approved
✓
✓
✓
✓
✓
capacity increased
86%
71%
70%
47%
FY21
FY22
FY23
FY24
15
R&D Capabilities
y t i l i c a f d e v o r p p a R I S D
15* DMFs
9* CEPs
4* CEPs in process
4* Process Patent Filed in India
10* CADIFA Brazil
Supported by R&D driven mindset
• A team of 60+ scientists primarily focused on API process development across the value chain
• Strong portfolio
in key therapeutic areas, decongestants, cardiovascular, central nervous system, COPD, etc
including anesthetics, anti-asthmatics, antihistamines,
• Consistent efforts to develop new products, improve existing formulations, enhance drug delivery systems,
and expand product applications.
Q3 FY25 Earnings Presentation
* As of December 2024
16
CMO Capabilities
• State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation
• Complete support in validation, stability, & compilation of dossiers
• Dedicated technology transfer team is periodically trained to enhance skills for timely scale-ups and validations
•
\
• Quality & regulatory team is well trained with latest guidelines to ensure on-time dossier submissions.
Q3 FY25 Earnings Presentation
17
Recently Commissioned State of The Art E Block
• Capacity: 335 KLPD
• Large volume equipment – multipurpose synthesis with focus on
backward integration capabilities
• Closed systems using gravity flow equipped with process control
system.
Q3 FY25 Earnings Presentation
18
FDF Facility ready for commissioning at Ambernath
Facility Location
• The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60,
Additional Ambernath MIDC, District Thane, Maharashtra, India (PIN: 421506) • Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International Airport.
R&D
• Dosage forms R&D being set up for tablets, capsules, liquids, sterile forms • Analytical laboratories & Complex API synthesis facilities alongside dosage forms
development for efficiency
• Focus areas – complex forms, anti-diabetics, anaesthetics.
Manufacturing
• Facilities under commissioning by Q4 FY 2025 • Tablets, capsules and liquids • Large volume liquids filling line • Validation and registration batches for dossier submissions.
Q3 FY25 Earnings Presentation
19
Complex Chemistries & Reaction
Focus on uniform manufacturing standards to achieve standardised product quality across markets
Ability to handle complex chemistries..
•
•
•
Simple to highly complex chiral molecules
Controlled substances
Products with specialized environment for manufacturing (Methylcobalamin, Vitamin B12 & derivatives)
s n o i t c a e r
f o s s a l c d e i r a v s s o r c a …
Cyclisation
High vacuum distillations Grignard reaction Fridel craft acylation
Decyanation
Etherification
Formylation
High pressure catalytic reductions
Bromination Nitration Oxirane
Q3 FY25 Earnings Presentation
20
Regulatory Achievements
Strong focus on compliance guided by ethical approach
• Our motto
is to consistently meet the stringent requirements of
regulatory bodies
• Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries from both authorities and customers.
50+
Registrations in different countries
10+
CEP’s
Q3 FY25 Earnings Presentation
500+
Customer Audit Approvals
15+
USDMF’s
21
Number of API’s Under Pipeline
API’s Under Pipeline
USDMF’s
18 API’s
CEP
USDMF
CEP
9 API’s
2 API
4 API’s
Status
Submitted
Granted
Submission Under Progress
Under Progress
CADIFA Brazil
10 API’s
Granted
Q3 FY25 Earnings Presentation
22
Awards & Accreditation
2009
Certificate of Excellence outstanding Export Performance in the product group Chemicals, Drugs, (MSME) awarded by Pharma and Allied Products Federation of Indian Export Organisation
for
2017
2019
2010
2016
Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India
Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra Export Achievement for 2015-16 in the product group Basic Products (MSME) Chemical, awarded by Government of Maharashtra
Pharmaceutical & Cosmetics
Directorate of
Industries,
Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra Export Achievement for 2016-17 in the product & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra
Chemical
group
Basic
Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of Indi
Q3 FY25 Earnings Presentation
23
Key Management Team
Satish Wagh Executive Chairman & WTD • B.Sc. from R.D National College and W.A. Science College, University of Bombay, Mumbai & an honorary Ph.D. in entrepreneurship from Faculty of Management
Studies, National American University
• Director on the boards of Supriya Medi-Chem Private Limited, Lote Industries Testing Laboratory Association and Sachin Industries Limited.
Saloni Wagh Managing Director • B.Sc. from Parle Tilak Vidhyalaya Association’s Sathaye College, University of Mumbai, Mumbai, a master’s degree in science from Institute of Science, University
of Mumbai, Mumbai and a PhD in chemistry from the Faculty of Science, Pacific University, Udaipur.
Shivani Wagh Joint Managing Director • Bachelor’s degree in management studies from M.L. Dahanukar College of Commerce, University of Mumbai, Mumbai and master’s degree in International
business management from Manchester Business School, University of Manchester, Manchester.
Krishna Raghunathan Chief Financial Officer • Chartered Accountant (CA) from ICAI and bachelor degree of Science in Zoology from Madras University, Chennai • Previously associated with companies like Dr. Reddy’s Laboratories Limited and Granules India Limited.
Q3 FY25 Earnings Presentation
24
EHS
Environment
Health
Safety
• Regular and strict monitoring to produce highest
• Clean, safe and healthy working environment for our
• Committed to safe and accident-free operations in all
efficiency in pollution control
all employees
• Mandatory medical examination and periodic
medical checkup
• Regular training workshops for employees involved in handling materials, operating various process, waste generation and treatment.
• Commitment to reduce, recycle and reuse all resources for conservation and waste reduction, wherever feasible
• Own ETP facility – 400 KLPD, 2000 KL retention
volume
• CETP membership – additional discharge of 260 KLPD • Over the years about 56% reduction in cost reduction
and relevant oil consumption
• Focus on solvent recovery, reduced emissions
• Adoption of paperless culture since 2015
•
Implementation of ERP system has drastically reduced use of overall paper.
Q3 FY25 Earnings Presentation
our establishments
• Safeguarding our employees and
acquiring the knowledge of hazardous activities carried out in the neighborhood
facilities by industrial
• Frequent fire safety mock drills and intensive training safety awareness and
programs to adherence to safety policies
inculcate
• Periodic internal and external audit for ensuring
compliance to our safety policy.
25
CSR & Social Work
We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm
• Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the students in the nearby schools to promote education
Supporting and participating with NGOs in chosen fields
• • Utilization of CSR funding for drinking water scarcity in villages near
our factory site
• Contribution to Prime Minister National Relief Fund •
Support patients for cancer treatment
•
Fund raisers and donations to worthy social causes, etc.
Q3 FY25 Earnings Presentation
26
Historical Financial Performance
Consistent & Strong Financial Performance
Robust revenue growth
Capex Spend
… and, focus on profitability
+15.6%
5,300.5
5,703.7
4,609.4
3,911.9
3,195.4
1,457
1,078
949
+13.0%
2,140
1,732
1,236
1,518
1,289
899
1,730
1,191
1,063
734
179
94
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY24
EBITDA
PAT
Return on Net Worth
Healthy leverage profile
49.2%
46.0%
24.7%
12.9%
15.0%
0.55
0.26
FY20
FY21
FY22
FY23
FY24
FY20
FY21
0.04
FY22
0.03
FY23
0.00
FY24
Q3 FY25 Earnings Presentation
28
Working Capital Break-up
Inventory
Receivables
206
233
172
165
130
73
71
63
61
53
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY24
Payables
Net Working Capital
113
79
75
49
59
194
196
235
105
124
FY20
FY21
FY22
FY23
FY24
FY20
FY21
FY22
FY23
FY24
Q3 FY25 Earnings Presentation
29
Summary Statement of Profit and Loss
Particulars (in INR Mn)
Total Revenue
Cost of Materials Consumed
Changes in Inventories of Finished Goods and Work in Progress
Gross Profit
GP %
Employee Benefits Expense
Other Expenses
EBITDA
EBITDA %
Other Income
Depreciation and Amortisation Expense
EBIT
Finance Costs
PBT
Total Tax Expense
Profit for the year
PAT %
EPS
Q3 FY25 Earnings Presentation
FY24
5,703.7
1,914.3
303.1
3,486.3
61.1%
676.4
1,080.2
1,729.7
30.3%
106.4
158.1
1,678.0
21.1
1,656.9
465.8
1,191.1
20.9%
14.80
FY23
4,609.4
1,873.2
-65.1
2,801.3
60.8%
555.8
956.5
1,289.0
28.0%
94.9
118.2
1,265.7
30.8
1,234.9
336.3
898.6
19.5%
11.16
FY22
5,300.5
1,988.3
-30.3
3,342.4
63.1%
490.8
711.8
2,139.8
40.4%
75.8
101.2
2,114.4
42.0
2,072.4
554.4
1,518.1
28.6%
18.86
FY21
3,912.4
1,405.7
-124.5
2,631.2
67.3%
327.6
571.8
1,731.7
44.3%
49.8
67.6
1,713.9
40.8
1,673.1
437.2
1,236.0
31.6%
16.89
30
Summary Statement of Assets and Liabilities
Particulars (in INR Mn)
Mar 24
Mar 23
Mar 22
Mar 21
Particulars (in INR mn)
Mar 24
Mar 23
Mar 22
Mar 21
ASSETS
Non-current assets
(i) Property, plant and equipment
3,037.0
2,551.2
1,824.7
(ii) Right to Use Asset
(iii)Capital Work in progress
(iv) Intangible Assets
(v) Financial Assets
-Investments
(vi) Other Non- Current Assets
47.8
1,488.3
16.6
638.0
6.8
53.2
676.3
11.1
253.0
9.3
58.0
434.1
15.1
0.5
39.8
969.5
14.7
787.9
16.1
0.5
11.2
Total Non-current assets
5,234.5
3,553.9
2,372.2
1,800.0
Current assets
(i) Inventories
(ii) Financial Assets
-Trade receivables
-Cash and cash equivalents
-Bank balances other than above
-Other financial Assets
-Loans and Advances
(iii) Other current assets
Total Current Assets
TOTAL ASSETS
Q3 FY25 Earnings Presentation
852.5
1,157.7
923.1
724.8
1,116.8
749.6
0.0
45.1
6.9
1,207.2
3,978.1
9,212.4
846.6
852.5
723.3
64.1
5.5
999.2
4,648.9
8,202.8
1,151.8
1,657.8
621.3
60.3
5.7
555.3
4,975.3
7,347.5
735.0
435.0
457.8
30.2
5.4
266.5
2,654.6
4,454.7
EQUITY AND LIABILITIES EQUITY (i) Equity share capital (ii) Other equity Total Equity
LIABILITIES
Non-current liabilities
(i) Financial Liabilities
-Borrowings -Lease Liabilities -Other financial liabilities (ii) Provisions (iii) Deferred tax Liabilities Total Non-Current Liabilities
Current liabilities
(i) Financial liabilities
-Borrowings -Lease Liabilities -Trade payables -Other financial liabilities (iii) Provisions (ii) Other current liabilities Total Current Liabilities TOTAL EQUITY ANDLIABILITIES
161.0 7,992.7 8,153.7
161.0 6,833.6 6,994.6
161.0 5,995.8 6,156.8
146.4 2,539.5 2,685.8
0.0 50.2 0.0 8.0 231.5 289.7
0.0 4.7 595.7 15.7 3.7 149.2 768.9 9,212.4
0.0 54.9 0.0 58.7 136.8 250.4
166.2 3.5 642.3 8.2 8.4 129.2 957.8 8,202.8
0.0 53.0 0.0 29.3 111.5 193.8
213.0 8.2 489.7 7.9 4.1 274.0 996.9 7,347.5
0.0 20.7 194.9 13.0 80.1 308.6
701.3 0.0 510.2 5.7 9.1 234.0 1,460.2 4,454.7
31
Summary Statement of Cashflow
Particulars (in INR Mn)
Cash Flow from Operating Activities
Profit before Tax
Adjustment for Non-Operating Items
FY24
FY23
FY22
FY21
1,656.9
1,234.9
2,072.5
1,673.9
24.0
72.0
68.7
53.1
Operating Profit before Working Capital Changes
1,680.9
1,306.8
2,141.2
1,727.0
Changes in Working Capital
Cash Generated from Operations
Less: Direct Taxes paid
Net Cash from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activities
Net increase/ (decrease) in Cash & Cash equivalent
Cash and cash equivalents at the beginning of the year
Effect of exchange rate changes on Cash & Cash Equivalent
Cash and cash equivalents at the end of the year
Q3 FY25 Earnings Presentation
-171.4
1,509.5
-376.5
1,133.0
-356.4
950.4
-288.6
661.9
-1,735.7
-1,331.5
-223.6
-826.3
-33.7
-703.3
1,575.8
2,279.1
0.0
749.5
0.0
1,575.8
2,279.1
-1,043.5
1,844.0
1,097.6
-609.6
488.0
-598.2
1,496.5
1,386.3
892.8
0.0
-117.0
-299.9
799.3
-474.1
-149.3
175.9
747.1
0.0
922.9
32
Future Outlook
Future Outlook
Two new R&D centres
CMO/CDMO space
• The future of the company is deeply rooted in R&D, with significant progress made to
• Company understands large scale special chemical manufacturing and has experience in
enhance research capabilities
handling hazardous complex process chemistry
1. The R&D lab at Lote Parshuram spans 800 sqm and is equipped with 20 fume hoods. This facility focuses on lifecycle management, backward integration, new product development, and CMO/CDMO opportunities
2. The Ambernath R&D lab is now fully operational, supporting the next phase of the
company’s expansion and innovation strategy.
• These centres will help to develop identified APIs which will complement existing product
profile
• The controlled drugs portfolio is set to be expanded, with potential APIs already identified and currently in the development pipeline. Additionally, the company is evaluating product portfolio expansion by selecting new products in the anti-diabetic and anesthetic segments.
•
Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products as per their needs
• We have recently announced one of our key CMO project with a leading European company where we will be exclusive API supplier. The contract spans a period of 10 years and is expected to generate peak revenue of 60 Crs/year starting from FY27
•
In addition to the aforementioned contract, the company has identified two similar opportunities in the API and advanced intermediate space, along with several other potential opportunities.
New markets
Capacity enhancement
• Company is currently doing business with over 1500+ customers and has presence in more
• Commissioned State-of-the-Art Module E Production Block at Lote Parshuram, boosting
than 120+ countries
our capacity by over 55%, increasing it from 597 KLPD to 932 KLPD
• The geographical locations are distributed within sales team to focus on sustaining the
business and expansion through new customer acquisition
• For regulated market, regulatory team is registering the products and filling DMFs. Sales team is in discussion with new customers to qualify us as a reliable source and started sending samples and supplying APIs for their product validation
• Company has taken additional steps for business expansion around the globe especially in
North America, Japan, Australia and New Zealand.
Q3 FY25 Earnings Presentation
• Capacity enhancement for further backward integration of existing products, new product
rollouts and CMO/CDMO opportunities
• We are developing a new formulation facility in Ambernath, along with an R&D facility
dedicated to the development of innovative products.
34
Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com
Orient Capital (a division of Link Group)
Mr. Irfan Raeen +91 97737 78669 irfan.raeen@linkintime.co.in
Ms. Prachi Ambre +91 83559 85370 prachi.ambre@linkintime.co.in
THANK YOU